DeepCure's Laparoscopic RDN Device Advances in Domestic Clinical Trials "Successful Completion of Surgery on Second Patient"

DeepCure's domestically clinical trial of the world's first laparoscopic renal denervation (RDN) medical device is progressing smoothly.

On the 7th, DeepCure announced that under the leadership of Professor Hwang Euichang from the Department of Urology and Professor Park Hyukjin from the Department of Cardiology at Hwasun Chonnam National University Hospital, the research team successfully completed the second clinical surgery on a patient using the laparoscopic RDN medical device 'HyperQure™'.

The patient participating in this clinical trial had severe refractory hypertension, maintaining a systolic blood pressure above 200 mmHg despite taking more than seven antihypertensive medications, resulting in emergency room visits and a very high potential risk of severe cardiovascular disease. In addition to the main renal artery, the patient had multiple accessory renal arteries. The sympathetic nerves passing through the accessory renal arteries significantly affect blood pressure regulation along with those passing through the main renal artery.

However, existing RDN treatments had limitations in treating accessory renal arteries smaller than 3 millimeters (mm) due to access restrictions. Using HyperQure for laparoscopic RDN, the company completely performed the nerve denervation. The patient’s side reported that blood pressure nearly normalized immediately after the clinical surgery, allowing partial discontinuation of antihypertensive drugs and discharge.

HyperQure is the world's first device that uses a high-frequency electrode-equipped instrument to treat hypertension by laparoscopically blocking the sympathetic nerves around the renal artery. It approaches from outside the blood vessel, perfectly blocking the renal nerves without damaging the vascular endothelium, treating patients with resistant hypertension whose blood pressure is uncontrolled despite taking three or more medications.

The company plans to perform surgery on a third patient domestically by May. Additionally, it will accelerate global clinical trials aiming to become the first in the world to receive approval for a laparoscopic RDN device.

Earlier in February, the company successfully conducted the first surgery using HyperQure with the team of Professor Shin Jin-ho from the Department of Cardiology and Professor Cho Jung-gi from the Department of Urology at Hanyang University Hospital. The first patient, who had taken five medications without blood pressure reduction, saw blood pressure immediately return to normal levels after laparoscopic RDN surgery. At the three-month follow-up, the 24-hour average blood pressure was controlled at 104/70, and medication reduction is planned.

A DeepCure representative stated, "The second patient who underwent laparoscopic RDN surgery also had blood pressure controlled within the normal range immediately after surgery and was discharged in good health," adding, "We expect to change the treatment paradigm for resistant hypertension through the laparoscopic RDN device, which overcomes the limitations of existing catheter-based methods such as vascular endothelium damage risk and incomplete nerve denervation."

This content was produced with the assistance of AI translation services.